Cargando…

Metformin and Everolimus: A Promising Combination for Neuroendocrine Tumors Treatment

Introduction: Treatment options for neuroendocrine tumors (NETs) are rarely curative, as NETs frequently show resistance to medical therapy. The use of everolimus, an mTOR inhibitor, is limited by the development of resistance, probably due to the activation of Akt signaling. In this context, the an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vitali, Eleonora, Boemi, Ilena, Tarantola, Giulia, Piccini, Sara, Zerbi, Alessandro, Veronesi, Giulia, Baldelli, Roberto, Mazziotti, Gherardo, Smiroldo, Valeria, Lavezzi, Elisabetta, Spada, Anna, Mantovani, Giovanna, Lania, Andrea G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464161/ https://www.ncbi.nlm.nih.gov/pubmed/32748870 http://dx.doi.org/10.3390/cancers12082143

Ejemplares similares

FLNA is implicated in pulmonary neuroendocrine tumors aggressiveness and progression
por: Vitali, Eleonora, et al.
Publicado: (2017)

Case Report: New CDKN1B Mutation in Multiple Endocrine Neoplasia Type 4 and Brief Literature Review on Clinical Management
por: Lavezzi, Elisabetta, et al.
Publicado: (2022)

A Multicenter Cohort Study in Patients With Primary Empty Sella: Hormonal and Neuroradiological Features Over a Long Follow-Up
por: Carosi, Giulia, et al.
Publicado: (2022)

COVID-19 ed endocrinologia: il caso della tiroide, del diabete e dell’ipovitaminosi D
por: Antonini, Simone, et al.
Publicado: (2021)

Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study
por: Piccini, Sara, et al.
Publicado: (2023)

ACTH Stimulation Test for the Diagnosis of Secondary Adrenal Insufficiency: Light and Shadow
por: Birtolo, Maria Francesca, et al.
Publicado: (2023)

The Number of Metastatic Lymph Nodes is a Useful Predictive Factor for Recurrence after Surgery for Nonmetastatic Nonfunctional Neuroendocrine Neoplasm of the Pancreas
por: Capretti, G., et al.
Publicado: (2019)

Evaluation of the ex vivo Effects of Tamoxifen on Adipose-Derived Stem Cells: A Pilot Study
por: Boemi, Ilena, et al.
Publicado: (2021)

Outcome of Sars-COV-2-related thyrotoxicosis in survivors of Covid-19: a prospective study
por: Pizzocaro, Alessandro, et al.
Publicado: (2021)

Urinary 5-Hydroxyindolacetic Acid Measurements in Patients with Neuroendocrine Tumor-Related Carcinoid Syndrome: State of the Art
por: Rossi, Roberta Elisa, et al.
Publicado: (2023)

Osteosarcopenia in autoimmune cholestatic liver diseases: Causes, management, and challenges
por: Pugliese, Nicola, et al.
Publicado: (2022)

PMON171 DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Pituitary Neuroendocrine Tumoral Cells
por: Mangili, Federica, et al.
Publicado: (2022)

The benefit of statins in SARS-CoV-2 patients: further metabolic and prospective clinical studies are needed
por: Bifulco, Maurizio, et al.
Publicado: (2020)

Emerging use of everolimus in the treatment of neuroendocrine tumors
por: Gajate, Pablo, et al.
Publicado: (2017)

Safety and Efficacy of Everolimus in Adult Patients with Neuroendocrine Tumors
por: Oberstein, Paul E., et al.
Publicado: (2012)

Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors
por: Yim, Kein-Leong
Publicado: (2012)

Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms
por: Daskalakis, Kosmas, et al.
Publicado: (2019)

Weight change and glycemic control in type 2 diabetes patients during COVID-19 pandemic: the lockdown effect
por: Biamonte, Emilia, et al.
Publicado: (2021)

DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells
por: Mangili, Federica, et al.
Publicado: (2022)

Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors
por: Berardi, Rossana, et al.
Publicado: (2017)

Gestione clinica della terapia con Denosumab: in chi, quando e come interromperla
por: Pigni, Stella, et al.
Publicado: (2023)

Treatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus
por: Cen, Putao, et al.
Publicado: (2012)

Effectiveness and Prognostic Factors of Everolimus in Patients with Pancreatic Neuroendocrine Neoplasms
por: Kurita, Yusuke, et al.
Publicado: (2022)

Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors
por: Di Giacinto, Paola, et al.
Publicado: (2018)

Prediction of vertebral fractures in cancer patients undergoing hormone deprivation therapies: Reliability of who fracture risk assessment tool (frax) and bone mineral density in real-life clinical practice
por: Mazziotti, Gherardo, et al.
Publicado: (2022)

Metformin Potentiates the Anticancer Effect of Everolimus on Cervical Cancer In Vitro and In Vivo
por: Chen, Ya-Hui, et al.
Publicado: (2021)

Combined Use of Metformin and Everolimus Is Synergistic in the Treatment of Breast Cancer Cells
por: Wang, Yunshan, et al.
Publicado: (2015)

Synergic Effect of Metformin and Everolimus on Mitochondrial Dynamics of Renal Cell Carcinoma
por: Hong, Seong-Hwi, et al.
Publicado: (2022)

Addressing the Role of Angiogenesis in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus: A Biological Prospective Analysis of Soluble Biomarkers and Clinical Outcomes
por: Cella, Chiara Alessandra, et al.
Publicado: (2022)

Efficacy and Safety of Everolimus plus Somatostatin Analogues in Patients with Neuroendocrine Tumors
por: Ge, Wenhao, et al.
Publicado: (2018)

Dopamine and Somatostatin Analogues Resistance of Pituitary Tumors: Focus on Cytoskeleton Involvement
por: Peverelli, Erika, et al.
Publicado: (2015)

Parathyroid hormone pulsatility: physiological and clinical aspects
por: Chiavistelli, Silvia, et al.
Publicado: (2015)

Metformin and the promise of geroprotection
por: Kalra, Sanjay, et al.
Publicado: (2012)

A phase Ib study of everolimus combined with metformin for patients with advanced cancer
por: Molenaar, Remco J., et al.
Publicado: (2017)

Serum testosterone mirrors inflammation parameters in females hospitalized with COVID-19
por: Birtolo, M. F., et al.
Publicado: (2022)

Procoagulant Imbalance in Klinefelter Syndrome Assessed by Thrombin Generation Assay and Whole-Blood Thromboelastometry
por: Indirli, Rita, et al.
Publicado: (2020)

The complementary role of PSMA expression and [(18)F]FDG PET/CT in predicting thyroid cancer outcome: from black and white to shades of gray, in the era of precision oncology
por: Sollini, Martina, et al.
Publicado: (2023)

Metformin prevents cell tumorigenesis through autophagy-related cell death
por: De Santi, Mauro, et al.
Publicado: (2019)

Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus
por: Sciammarella, Concetta, et al.
Publicado: (2020)

Everolimus in poorly differentiated neuroendocrine carcinoma of unknown primary: A case report
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ufekj4h9jkm3qbkoatr92i8qia